QIAGEN expands QIAsymphony test menu in partnership with Seegene
Initial focus will be multiplex assays for infectious diseases on flagship automation platform
HILDEN, Germany, and SEOUL, South Korea, July 8, 2015 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced a collaboration in which Seegene Inc. (096530.KQ) will develop a menu of multiplex assay panels for its modular QIAsymphony RGQ MDx automation platform.
The first project is to develop comprehensive panels to profile infectious diseases. Seegene’s proprietary technologies for multiplexed real-time PCR analysis enable simultaneous amplification of up to 20 target genes per tube in a single reaction. QIAGEN will validate the new tests to run on QIAsymphony RGQ MDx, its flagship automation solution, and will market them worldwide as QIAGEN-branded assays, beginning in Europe and Asia.
“We are excited to bring to our customers valuable new tests for QIAsymphony RGQ MDx by partnering with Seegene to develop and commercialize novel multiplex assays. Seegene’s technologies can test for multiple targets with high sensitivity, reproducibility, and the panels offer significant medical value”, said Thierry Bernard Senior Vice President, Head of the Molecular Diagnostics Business Area and a member of the Executive Committee of QIAGEN. “QIAsymphony is adding significant value for users as the growing menu of clinically proven diagnostics allows labs to consolidate more tests on one system. The new tests will be highly synergistic with our current menu. Already one of the most widely placed medium-throughput systems, QIAsymphony is revolutionizing workflows with cost-effective processing from sample to insight.”
Dr. Jong-Yoon Chun, Founder and CEO of Seegene, said: “Collaborating with QIAGEN to commercialize comprehensive multiplexed panels based on our innovative PCR chemistry technologies will expand Seegene’s global reach. Because our breakthrough MuDT technology enables detection and quantification of multiple target genes in a single channel without melt curve analysis, this is a true next-generation qPCR technology. We look forward to working with QIAGEN to create innovative assay panels that improve life for patients and meet the workflow needs of molecular laboratories.”
QIAsymphony is an innovative, easy-to-use modular system that integrates a molecular laboratory's workflow from initial biological sample processing to final insights. The three modules of QIAsymphony RGQ MDx are QIAsymphony SP for sample preparation, QIAsymphony AS for assay setup (integrated into the SP module), and QIAGEN's real-time PCR detection platform Rotor-Gene Q MDx. QIAsymphony RGQ MDx received FDA clearance in early 2014.
The menu of diagnostics running on the QIAsymphony platform so far includes 13 CE-IVD marked tests available in 30 European countries and six FDA-approved or cleared diagnostics in the United States. QIAGEN’s first highly multiplexed assay running on Rotor-Gene Q, the RespiFinder RG Panel for detection and differentiation of 21 respiratory pathogens, was recently launched in Europe.
Seegene is the world’s leading developer of multiplex molecular technologies and multiplexed clinical molecular diagnostics. Seegene’s innovative proprietary technologies, including DPO™, TOCE™, mTOCE™ and MuDT™, can simultaneously detect multiple targets with high sensitivity, specificity and reproducibility. Seegene’s products detect multi-pathogens with great reliability and throughput, ultimately providing the most economical basis for saving time, labor and cost. Seegene endlessly strives toward the new possibility of a world free of disease. For more information, please visit www.seegene.com or call +301-762-9066.
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. QIAGEN sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective molecular testing workflows. QIAGEN provides these workflows to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). As of September 30, 2014, QIAGEN employed approximately 4,200 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, markets, strategy or operating results, including without limitation its expected operating results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products in applied testing, personalized healthcare, clinical research, proteomics
, women's health/HPV testing and nucleic acid-based molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products, the consummation of acquisitions, and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).